New for 2027: BHRT Certification Training, Now 12 CME Credits
Our completely rebuilt BHRT certification training course was officially released on October 1, 2026. Version 15 is the largest revision in the history of PracticalCME: every slide rewritten, every section re-narrated, and 180+ clickable references to primary literature, specialty society guidelines, FDA actions and approved drug labels placed on the slide where each claim is made. It carries 12.0 AMA PRA Category 1 Credits or 12.0 ANCC contact hours, including 7.0 pharmacotherapeutic hours, for MD, DO, PA, NP and RN.
Why BHRT, and Why Now
Peptide therapy is where the attention is. It is not where the stable practice revenue is, and clinicians who added peptides first are discovering why.
The molecules are the difference. Estradiol, progesterone, testosterone, levothyroxine, liothyronine and hydrocortisone are FDA-approved drugs with approved products, published labels, USP monographs and decades of pharmacovigilance. When a compounded preparation is appropriate, the Section 503A pathway for these substances is settled law, and the course teaches exactly where that line sits. Compare that with the peptides currently driving clinic marketing: several of the best known are not eligible for compounding at all, and others sit in an unsettled regulatory space that has already produced warning letters and enforcement action.
This is the service peptides cannot replace. Growth hormone secretagogues work downstream of thyroid and cortisol. Tissue repair peptides are blunted by an elevated cortisol curve. Sexual function peptides are routinely prescribed for symptoms that originate in untreated testosterone, estrogen or thyroid deficiency. A provider who cannot test and correct the endocrine baseline is treating the symptom and billing for the guess. Hormone optimization is the diagnostic foundation underneath every wellness service you offer, including weight loss, where unaddressed thyroid and cortisol dysfunction are the headwinds that stall a GLP-1 program.
The FDA Just Signaled Interest in Female Testosterone Therapy
On September 17, 2026, the FDA Office of Women’s Health and CDER held a public workshop on testosterone use in menopausal women, the agency’s first comprehensive look at this question in roughly two decades. FDA presenters stated they are ready to talk with drug sponsors about bringing these products to American women, and the public comment docket (FDA-2026-N-5479) is open through October 19, 2026.
There is still no FDA-approved testosterone product for women in the United States. That may change. The workshop also reaffirmed the conservative clinical position this course has taught for years: postmenopausal hypoactive sexual desire disorder is the only evidence-based indication, levels do not diagnose symptoms, measurement requires mass spectrometry rather than immunoassay, and supraphysiologic dosing by pellet is a risk without an off switch. Clinicians who learn the defensible version of this therapy now will be ready when the regulatory landscape moves.
What You Learn
- Salivary hormone testing done correctly: collection technique, the errors that manufacture a false result, and where the method is well supported versus where it is not
- Female hormone therapy: perimenopause and menopause, delivery routes, endometrial protection rules, cyclic symptoms, and vaginal atrophy
- Male testosterone therapy: diagnosis, the contraindications that should stop you, and the hematocrit and PSA numbers that trigger referral
- Thyroid testing and treatment, including T4 and T3 combination therapy and desiccated thyroid conversion arithmetic
- Four-point salivary cortisol and treatment of stress-induced HPA axis dysfunction, in sequence, from lifestyle through hydrocortisone
- Practice implementation: coding, documentation, advertising limits, supplement ethics, and a worked case series
How This Course Is Different
No sponsors control the curriculum. No fad products, no multi-level marketing supplements, and no claim that bioidentical hormones are categorically safer than synthetics, because that claim is not established and the FDA has cautioned against making it. Where the published evidence does not support a practice, the course says so. Where the author’s twenty years of clinical observation goes beyond the literature, it is labeled as observation. That distinction is why this training survives scrutiny from a medical board, a malpractice reviewer or a skeptical colleague.
Taught exclusively by board-certified MD faculty. Self-paced streaming, two years of access, free updates as drug labeling and guidance change, and an accredited CME certificate you download and print the moment you pass the post-test.
Review the full course outline and enroll in BHRT certification training. Already running a peptide or IV service? Pair it with our Peptides, IVs and GLP-1s course and build the testing foundation underneath it.